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Abstract: 
 
Bacterial efflux pumps are active transport proteins responsible for resistance to selected 
biocides and antibiotics. It has been shown that production of efflux pumps is up-regulated in a 
number of highly pathogenic bacteria, including methicillin resistant Staphylococcus aureus. 
Thus, the identification of new bacterial efflux pump inhibitors is a topic of great interest. 
Existing assays to evaluate efflux pump inhibitory activity rely on fluorescence by an efflux 
pump substrate. When employing these assays to evaluate efflux pump inhibitory activity of 
plant extracts and some purified compounds, we observed severe optical interference that gave 
rise to false negative results. To circumvent this problem, a new mass spectrometry-based 
method was developed for the quantitative measurement of bacterial efflux pump inhibition. The 
assay was employed to evaluate efflux pump inhibitory activity of a crude extract of the 
botanical Hydrastis Canadensis, and to compare the efflux pump inhibitory activity of several 
pure flavonoids. The flavonoid quercetin, which appeared to be completely inactive with a 
fluorescence-based method, showed an IC50 value of 75 μg/mL with the new method. The other 
flavonoids evaluated (apigenin, kaempferol, rhamnetin, luteolin, myricetin), were also active, 
with IC50 values ranging from 19 μg/mL to 75 μg/mL. The assay described herein could be 
useful in future screening efforts to identify efflux pump inhibitors, particularly in situations 
where optical interference precludes the application of methods that rely on fluorescence. 
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Abstract
Bacterial efflux pumps are active transport proteins responsible for resistance to selected
biocides and antibiotics. It has been shown that production of efflux pumps is up-regulated
in a number of highly pathogenic bacteria, including methicillin resistant Staphylococcus
aureus. Thus, the identification of new bacterial efflux pump inhibitors is a topic of great in-
terest. Existing assays to evaluate efflux pump inhibitory activity rely on fluorescence by an
efflux pump substrate. When employing these assays to evaluate efflux pump inhibitory ac-
tivity of plant extracts and some purified compounds, we observed severe optical interfer-
ence that gave rise to false negative results. To circumvent this problem, a new mass
spectrometry-based method was developed for the quantitative measurement of bacterial
efflux pump inhibition. The assay was employed to evaluate efflux pump inhibitory activity of
a crude extract of the botanical Hydrastis Canadensis, and to compare the efflux pump in-
hibitory activity of several pure flavonoids. The flavonoid quercetin, which appeared to be
completely inactive with a fluorescence-based method, showed an IC50 value of 75 μg/mL
with the new method. The other flavonoids evaluated (apigenin, kaempferol, rhamnetin,
luteolin, myricetin), were also active, with IC50 values ranging from 19 μg/mL to 75 μg/mL.
The assay described herein could be useful in future screening efforts to identify efflux
pump inhibitors, particularly in situations where optical interference precludes the applica-
tion of methods that rely on fluorescence.
Introduction
Bacterial efflux pumps are active transport proteins that function to extrude toxic compounds,
including antimicrobial drugs, from the cell. These pumps serve to protect bacteria from dam-
age by toxins, and can play a role in the development of resistance to antimicrobials [1–5]. For
example, it has been shown that production of efflux pumps is up-regulated in drug resistant
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strains of many bacteria, including methicillin resistant Staphylococcus aureus [6–10]. Com-
pounds that inhibit bacterial efflux pumps are of interest because of their potential to increase
antimicrobial effectiveness [11]. Thus, our laboratory has been engaged in experiments to find
new efflux pump inhibitors (EPIs) from natural product sources.
Current methods for evaluating efflux pump inhibitory activity rely on an efflux pump sub-
strate that fluoresces only when it is located inside a cell (due to intercalation with DNA) [12].
The majority of existing protocols operate by pre-loading cells with the efflux pump substrate
ethidium bromide, which gives them a high initial fluorescent intensity. The extent of efflux
pump inhibition is then measured by comparing the rate of decrease in fluorescence intensity
over time in the presence of varying amounts of the putative EPI [4,9,13–18]. Related experi-
ments utilizing measurements based on the intracellular accumulation of fluorescent substrates
have also been reported [9,19]. For accumulation experiments, fluorescence increases over
time as the substrate diffuses into cells.
Ethidium bromide is attractive as an indicator of efflux pump inhibition because of exten-
sive literature precedent and also because it has been established to be active via intracellular
action, with literature precedent stretching back to the 1950s [12,20,21]. However, the existing
methods for testing efflux pump inhibition with ethidium bromide gave false results in our
study due to matrix quenching effects (the suppression of fluorescence by various components
of the mixture) in crude extracts and even with some pure compounds. We endeavored to cir-
cumvent these quenching effects by developing a new mass spectrometry-based efflux pump
inhibition assay. There is extensive literature support for the efflux pump inhibitory activity of
flavonoids and related compounds [9–11,16,22–29]; thus, we sought to validate the new assay
by comparing efflux pump inhibitory activity of a series of pure flavonoids. In addition, to test
the validity of the new assay in a more crude sample matrix, we compared the efflux pump in-
hibitory activity of an extract from the botanical goldenseal (Hydrastis canadensis), which is
known to contain EPIs [10,16], using both fluorescence and mass spectrometry-based ap-
proaches for data collection.
Materials and Methods
Preparation of plant material
The goldenseal leaf and petiole material used was cultivated in a woodland setting in Hender-
sonville, North Carolina, (N 35°24.2770', W 082°20.9930', 702.4 m elevation) and was made
available by William Burch; this population has been utilized in previously published work
[10,16] and is represented by a voucher (NCU583414) curated in the University of North Caro-
lina at Chapel Hill herbarium. The goldenseal extract was prepared using previously described
methods [10,30]. Dried plant material was macerated for at least 24 hr, and the methanol ex-
tract was subsequently separated from the plant material. This extract was dried in a rotary
evaporator to reduce the volume of methanol, and partitioned against an equal volume of hex-
ane. The resulting mixture was stirred for at least one hr and the layers were collected separate-
ly using a separatory funnel. The methanol partition was added to water and chloroform in a
ratio of 1:5:4, stirred for at least 1 hr, then separated. The chloroform partition from this step
was evaporated and used as the starting material for all experiments described herein, and will
be referred to as “goldenseal extract” from this point forward.
96 well plate ethidium bromide accumulation assay
This assay is an adaptation of published ethidium bromide efflux-based assays [16–18] and
previously published reports of measurements on intracellular accumulation of berberine and
chloramphenicol [9,19]. All experiments presented here were performed in the 96 well plate
Measurement of Efflux Pump Inhibition with Mass Spectrometry
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format. Activity was tested using Staphylococcus aureus strain NCTC 8325–4 [31]. The final
assay composition was 10% DMSO, 50%Muller-Hinton broth, 40% water (by volume), an esti-
mated 1.6–1.8x108 CFU/mL S. aureus, 1.25 μg/mL ethidium bromide, and a range of analyte
concentrations. Data collection, and hence bacterial exposure to these conditions, was limited
to 30 min. The alkaloid piperine was used as a positive control, as it is well established in the lit-
erature to be an EPI [25,32,33]. Each analyte concentration was tested in triplicate, and the pos-
itive control (a piperine dilution series ranging from 4.7 μg/mL to 300 μg/mL prepared via
2-fold dilution) was included on each plate. Fluorescence was measured using a BioTek Syner-
gyH1 microplate reader (BioTek, Winooski, VT) with an excitation wavelength of 520 nm and
emission wavelength of 600 nm at 1 min intervals for a total of 30 min. All experiments were
performed in triplicate and error bars reported as standard deviation.
Use of mass spectrometry to measure ethidium bromide accumulation
To enable mass spectrometric measurements of ethidium bromide accumulation, the experi-
mental parameters were identical to those described in the previous section, except that the
method of data collection was modified. The prepared samples were incubated at room tem-
perature in a EMDMillipore MultiScreen fritted-bottom 96-well filter plate (pore size 0.22 μm,
EMDMillipore, Darmstadt, Germany). At the conclusion of the 30 min incubation period,
these were filtered simultaneously under vacuum into a receiving 96 well plate. All solutions
were stored at 4°C prior to analysis.
Ethidium bromide in the bacterial supernatant was analyzed using high performance liquid
chromatography (HPLC) electrospray ionization-mass spectrometry (ESI-MS). Liquid chro-
matography separations were achieved using a ThermoFinnigan Surveyer HPLC system
(Thermo Finnigan, San Jose, CA). The autosampler was temperature controlled at 8°C, and the
column (Agilent Prevail C18, 3 μm packing, 50 x 2.1 mm) was heated to 40°C. Sample injection
volume was 5 μL and a flow rate of 0.2 mL/min was employed. Samples were eluted using bina-
ry gradients consisting of acetonitrile acidified with 1% acetic acid and deionized water
(CH3CN:H2O) as follows:—0 min, 0:100; 1.5 min, 0:100; 2 min, 95:5; 10 min, 95:5; 10.5 min,
0:100; 18 min, 0:100. Mass spectrometry analyses were conducted with an LCQ DECA XP Plus
ion trap mass spectrometer with electrospray ionization source (Thermo Fisher Scientific)
using the following conditions: capillary temperature, 250°C; sheath gas flow, 10 (arbitrary
units); no auxiliary gas; source voltage 4.5 kV; capillary voltage, 42 V; tube lens offset, -25 V.
The instrument was operated in the positive ion mode with two scan events. The first was full
scan, followed by the data-dependent CID fragmentation (50% collision energy) ofm/z 314.20
(the [M]+ ion of ethidium). The selected ion chromatogram was plotted for the main product
ionm/z 286, and its peak area was determined. All experiments were performed in triplicate
and error bars set to standard deviation.
Mass spectrometry data were analyzed to determine an IC50 value for each test compound.
The IC50 of piperine was defined as the midpoint between the peak area for vehicle control and
that of the 300ppm piperine sample, similar to an approach employed previously [34]. Once
determined for piperine, the same peak area was used as a set point for determining IC50 values
of the test compounds on the same plate.
Bacterial growth inhibition
MICs were determined according to Clinical Laboratory Standards Institute guidelines [35].
Solutions were prepared in 96 well plates with a final well volume of 250 μL, 2% DMSO in
Mueller-Hinton broth, and variable concentrations of test compound or extract ranging from
4.7 to 150 μg/mL, prepared in triplicate. Duplicate plates of each experiment were employed,
Measurement of Efflux Pump Inhibition with Mass Spectrometry
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one inoculated with a bacterial concentration of 5x105 CFU/mL, the other containing only ana-
lyte and vehicle. All plates were incubated for 18 hr at 37°C, after which turbidity at 600nm
(OD600) was measured with a BioTek Synergy H1 microplate reader. To correct for back-
ground due to absorbance of the analyte compounds, the mean OD600 for each treatment with-
out addition of bacteria was subtracted from the mean OD600 of treated wells. MIC was
determined as the concentration where there was no statistically significant difference between
the mean absorbance of the treated wells and that of the negative control (vehicle in broth).
Results and Discussion
Assay development and comparison of efflux pump inhibition assay
methods
The first goal of our experiments was to determine the applicability of a fluorescence-based ac-
cumulation assay to measure the efflux pump inhibitory activity of various flavonoids. Towards
this goal, we first validated the assay using a known efflux pump substrate (ethidium bromide)
and a known EPI (piperine). As expected, when S. aureus is exposed to ethidium bromide, fluo-
rescence increases over time (Fig 1). This increase is due to intracellular accumulation of ethid-
ium, which fluoresces at 600 nm when it is intercalated with DNA [16]. Ethidium bromide is a
substrate of NorA, a major chromosomally-encoded Staphylococcus aureus efflux pump [3,5].
Thus, the intracellular accumulation of ethidium bromide by S. aureus is counteracted by the
Fig 1. Change in absolute fluorescent intensity over time for Staphylococcus aureus exposed to ethidium bromide in the efflux pump inhibitor
piperine. Fluorescence increases over time due to intracellular accumulation of ethidium bromide. The increase is more pronounced in the presence of
piperine, which enhances intracellular accumulation of ethidium bromide by blocking efflux. Data points represent the mean of 3 samples, error bars
represent standard deviation.
doi:10.1371/journal.pone.0124814.g001
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action of NorA (and other efflux pumps). As evidence of this, the addition of piperine, a
known NorA inhibitor, caused a more pronounced increase in fluorescence over time than was
observed for the cells in the absence of the inhibitor (Fig 1).
Plotting the time-dependent accumulation assay data (Fig 1) at only a single time point
(30 min) allows them to be represented as a dose-response curve (Fig 2A), with mean fluores-
cent intensity at one concentration on the y-axis, and test compound concentration on the x-
axis. These curves demonstrate that ethidium bromide efflux is inhibited in the presence of pip-
erine, and that this inhibition is dose-dependent (Fig 2A).
After the positive control was validated with the above methodology, the same approach
was used to measure efflux inhibitory activity of several purified flavonoids. Flavonoids were
chosen as test compounds because they are ubiquitous in plants, and by extension in plants
that are used for food and for medicine [36,37]; and because numerous reports indicate that
many flavonoids possess EPI activity [9–11,16,22–29]. Consistent with this precedent, the fla-
vonoid apigenin displayed clear evidence of efflux pump inhibition (Fig 2A). However, the fla-
vonoid quercetin appeared to be inactive. The unexpected negative result for quercetin led to
the suspicion that optical matrix interference (quenching of ethidium bromide fluorescence)
could interfere with accurate determinations of EPI activity of some compounds. To evaluate
this possibility, a series of samples was prepared that included constant concentrations
(150 μg/mL) of piperine, along with varying concentrations of the suspected quenching agent
quercetin (Fig 2B). It is clear that as the concentration of quercetin increases in these solutions,
the overall fluorescence of the mixture decreases, presumably due to quenching. Consistent
with this observation, there are many reports of quenching in fluorescence-based assays, espe-
cially when plant extracts are involved [38–42].
To circumvent the problem with optical matrix interference, a method was developed using
liquid chromatography—mass spectrometry (LC-MS) to measure ethidium bromide concen-
trations in the spent broth filtrate. The concentration-response relationship for the data gener-
ated by the LC-MS method was expected to be the inverse of that generated by the
measurement of fluorescence—as the concentration of an inhibitor increases, it traps the ethid-
ium inside the bacterial cells, and the concentration of ethidium in the spent broth filtrate (as
measured by LC-MS) should decrease. The known EPI piperine was again used for assay vali-
dation and it was observed that, as expected, the concentration of ethidium in the filtrate de-
creased with increasing concentration of piperine (Fig 3A). These results were plotted in a
dose-response curve, with peak area displayed on the y-axis and concentration on the x-axis
(Fig 3B).
With the LC-MS assay, it is possible to quantify the extracellular levels of ethidium without
relying on fluorescence. Thus, if quercetin is in fact an active EPI and the negative results ob-
served in the fluorescence based assay (Fig 2) are due to quenching, quercetin should have de-
monstrable activity in the new LC-MS based assay. Consistent with this expectation, the
LC-MS based method showed quercetin to be active as an EPI (Fig 3B). Once the confounding
effect of quenching is removed, it is apparent that quercetin is similar in its EPI activity to pip-
erine, and apigenin is the most active EPI of the three. Furthermore, the LC-MS method
showed a more typical dose-response relationship for apigenin (Fig 3B) compared to the fluo-
rescence-based assay (Fig 2A), suggesting that apigenin quenches ethidium fluorescence at
concentrations 38 μg/mL.
To further evaluate the applicability of the LC-MS based efflux pump inhibition assay, we
measured IC50 values (Table 1) for a series of six structurally diverse flavonoids and two
known EPIs, the aforementioned compound piperine, and carbonyl cyanide m-chloro-phenyl-
hydrazone (CCCP) [9,10,14,16,19]. All six flavonoids were active (sample data shown in Fig 4),
with IC50 values ranging from 19 μg/mL (kaempferol and rhamnetin) to 75 μg/mL (quercetin,
Measurement of Efflux Pump Inhibition with Mass Spectrometry
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luteolin, and myricetin.) (Table 1). Piperine demonstrated an IC50 value in this assay between
75 μg/mL and 150 μg/mL, and CCCP was the most active of all compounds tested (IC50
4.7 μg/mL, Table 1).
Finally, it was of interest to evaluate whether the mass spectrometry-based efflux assay
would be applicable to samples with more complex matrices. Toward this goal, a botanical ex-
tract prepared from goldenseal (Hydrastis canadensis) was evaluated for EPI activity using
both the fluorescence-based and mass spectrometry-based ethidium bromide accumulation as-
says. When assayed by the fluorescence-based method, the extract appeared inactive (no appar-
ent IC50, Fig 5A), contradicting literature that indicates H. canadensis extracts contain EPIs
[10,16]. However, when the activity of the extract was evaluated with the mass spectrometry-
based assay, an IC50 value of 75 μg/mL was observed (Fig 5B). These results demonstrate that
quenching can hamper the measurement of efflux pump inhibition for complex extracts using
fluorescence, and that the interference can be overcome using the method developed herein.
This finding is particularly important given that it may be useful in drug discovery efforts to
screen complex extracts for the presence of EPIs.
Potential interference by growth effects
Many botanical compounds possess antimicrobial activity. Thus, it was important to evaluate
whether growth effects might confound the measurements of efflux pump inhibition. Towards
this goal, the flavonoids, controls, and the goldenseal extract were screened for inhibition of
bacterial growth across a range of concentrations, from 4.7 μg/mL to 150 μg/mL. Only three
samples, the flavonoids luteolin and myricetin, and the known EPI CCCP, demonstrated mea-
sureable MICs under these conditions (Table 1). To determine whether growth inhibition by
these compounds was likely to confound data interpretation, the two inhibitory flavonoids
(luteolin and myricetin) were incubated with test strains under the experimental conditions at
twice their IC50 values (Table 1). S. aureus cells were tested for loss of viability in the presence
of these flavonoids (as well as in the presence of the flavonoid apigenin which does not inhibit
Fig 2. Change in fluorescence due to ethidium accumulation by S. aureus in the presence of putative inhibitors. (A) Dose-response curves for the
flavonoids apigenin and quercetin. (B) Fluorescence observed for 150 μg/mL piperine in the presence of increasing concentrations of quercetin. Decrease in
fluorescence with increasing quercetin concentration in (B) can be attributed to fluorescence quenching by the flavonoid. Data points represent the mean of
triplicate measurements (biological replicates), error bars represent standard deviation.
doi:10.1371/journal.pone.0124814.g002
Fig 3. Representative selected chromatograms of filtered, spent broth showing a peak for the
ethidium ion (MS-MS transition ofm/z 314 to 286). Sample 1 is the negative control (S. aureus cultured for
30 min in Mueller Hinton broth with 1.25 μg/mL ethidium bromide and 10%DMSO), samples 2 and 3 were
cultured under the same conditions as sample 1 with the addition of 75 μg/mL and 300 μg/mL piperine,
respectively. All three peaks are normalized to a signal intensity of 3.45 x 106. As piperine is added, efflux
pumps are blocked, trapping the ethidium inside the cells and decreasing the quantity of ethidium (as
indicated by the area of the ethidium peak) in the spent broth.
doi:10.1371/journal.pone.0124814.g003
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bacterial growth) by replicating the experimental conditions of bacterial, ethidium bromide,
broth and DMSO content, and plating aliquots of the resulting culture onto supplemented
Mueller-Hinton agar at 0, 15 and 30 min time points. No loss of viability was observed after a
30 min exposure to the experimental conditions, as determined by colony count enumeration
(S1 Fig). Additionally, to further evaluate the potential for simple toxicity to confound evalua-
tion of data in this assay, the commercial antibiotics gentamicin and nafcillin were subjected to
Table 1. Efflux pump inhibitory activity and antimicrobial activity of flavonoids.
Flavonoid IC50 for efflux inhibition
a MICb
Apigenin 38 μg/mL (140 μM) >150 μg/mL (>560 μM)
Kaempferol 19 μg/mL (66.0 μM) >150 μg/mL (>520 μM)
Rhamnetin 19 μg/mL (60.0 μM) >150 μg/mL (>470 μM)
Quercetin 75 μg/mL (250 μM) >150 μg/mL (>500 μM)
Luteolin 75 μg/mL (260 μM) 75 μg/mL (260 μM)
Myricetin 75 μg/mL (240 μM) 150 μg/mL (470 μM)
CCCPc 4.7 μg/mL (23 μM) 0.29 μg/mL (1.4 μM)
a: Efflux pump inhibition was measured via LC-MS analysis of ethidium in spent, filtered culture
supernatant after a 30 min incubation in triplicate wells.
b: Growth inhibition was measured by optical density at 600nm (in triplicate) after an 18 hr incubation.
c: CCCP is an abbreviation for the compound carbonyl cyanide m-chloro-phenylhydrazone
doi:10.1371/journal.pone.0124814.t001
Fig 4. Efflux pump inhibitory activity of apigenin, piperine, and quercetin as indicated by LC-MSmeasurement of residual ethidium bromide in
spent broth after a 30 min incubation. Relative peak area (expressed as a percentage) for ethidium is plotted as a function of concentration of the putative
inhibitor. Data points represent the mean of 3 measurements (biological replicates), with error bars representing standard deviation.
doi:10.1371/journal.pone.0124814.g004
Measurement of Efflux Pump Inhibition with Mass Spectrometry
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Fig 5. Efflux pump inhibition in S. aureus by a goldenseal (Hydrastis canadensis) extract. (A) Data collected using the fluorescence-based ethidium
accumulation assay for a range of H. canadensis extract concentrations. (B) Data collected using the mass spectrometry-based ethidium accumulation
assay. Incubation time was 30 min for both A and B, data represents mean of 3 samples, error bars represent standard deviation.
doi:10.1371/journal.pone.0124814.g005
Measurement of Efflux Pump Inhibition with Mass Spectrometry
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the mass spectrometry-based efflux pump inhibition assays, and no IC50 was observed to the
maximum concentration tested of 100 μg/mL (S2 Fig). The highest tested concentration for the
antibiotics was well above their reported MICs against Staphylococcus aureus (~0.5 μg/mL
[43,44]). Collectively, these results suggest that growth inhibition does not confound the mea-
surements of efflux pump inhibitory activity reported in Table 1.
Conclusions
In light of the health risks posed by the increased occurrence of antibiotic resistant bacterial
strains, the need for reliable methods for their study is of high importance. The mass spectrom-
etry-based method to quantitatively investigate efflux pump inhibition is just such a tool, and
as such is expected to be of high value to the scientific community. Our study shows that mis-
leading results (false negative in the case of assays that rely on ethidium bromide accumula-
tion) can be obtained when screening crude extracts and even pure compounds with
fluorescence-based efflux pump inhibition assays. The new method presented here circum-
vents these problems. Additionally, the ubiquity of activity in the flavonoids tested in the vali-
dation process of this assay reinforces the importance of this class of natural products in the
reversal of efflux-pump mediated drug resistance.
Supporting Information
S1 Fig. Time series data evaluating the viability of Staphylococcus aureus cultures exposed
to experimental conditions. Conditions are as follows: 10% DMSO, 50% Muller-Hinton
broth, 40% water (by volume), with 1.25 μg/mL ethidium bromide, for a maximum of 30 min.
Test compounds include two flavonoids that inhibit the growth of this strain (luteolin and
myricetin), and one that does not (apigenin) (Table 1). (EPS)
(TIF)
S2 Fig. Efflux pump inhibitory data generated via the mass spectrometry-based assay per-
formed on the known antibiotic compounds gentamicin and nafcillin. Also shown is a con-
trol dose-response curve performed on the positive control piperine.
(TIF)
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